Accurate identification of Alzheimers disease (AD) using resting-state functional magnetic resonance imaging (rs-fMRI) remains challenging due to the high dimensionality, noise, and complex inter-regional dependencies inherent in functional brain connectivity, which limit the effectiveness of traditional approaches based on handcrafted connectivity features or conventional machine learning models. In this work, we present an attention-based deep learning framework for Alzheimers disease classification that operates directly on rs-fMRI functional connectivity matrices by treating brain regions as tokens and employing a Transformer-inspired self-attention mechanism to model long-range and global functional dependencies across distributed brain networks. The proposed framework learns discriminative functional representations without reliance on manual feature engineering and is evaluated on a longitudinal cohort from the Alzheimers Disease Neuroimaging Initiative (ADNI) comprising cognitively normal and Alzheimers disease subjects with multiple visits. A subject-wise evaluation protocol is adopted to prevent information leakage across visits, and class-weighted optimization is incorpo
Normative modeling learns a healthy reference distribution and quantifies subject-specific deviations to capture heterogeneous disease effects. In Alzheimers disease (AD), multimodal neuroimaging offers complementary signals but VAE-based normative models often (i) fit the healthy reference distribution imperfectly, inflating false positives, and (ii) use posterior aggregation (e.g., PoE/MoE) that can yield weak multimodal fusion in the shared latent space. We propose mmSIVAE, a multimodal soft-introspective variational autoencoder combined with Mixture-of-Product-of-Experts (MOPOE) aggregation to improve reference fidelity and multimodal integration. We compute deviation scores in latent space and feature space as distances from the learned healthy distributions, and map statistically significant latent deviations to regional abnormalities for interpretability. On ADNI MRI regional volumes and amyloid PET SUVR, mmSIVAE improves reconstruction on held-out controls and produces more discriminative deviation scores for outlier detection than VAE baselines, with higher likelihood ratios and clearer separation between control and AD-spectrum cohorts. Deviation maps highlight region-lev
Mathematical modeling offers a valuable approach to understanding Alzheimers disease (AD) given its complexity, unknown causes, and lack of effective treatments. Models, once validated, offer a powerful tool to test medical hypotheses that are otherwise difficult to verify directly. Our focus here is on elucidating the spread of misfolded tau protein, a critical hallmark of AD alongside Abeta protein, taking also into account the synergistic interaction between the two proteins. We consider distinct modelling choices, all employing network frameworks for protein evolution, differentiated by their network architecture and diffusion operators. By carefully comparing these models against clinical tau concentration data, gathered through advanced multimodal analysis techniques, we show that certain models replicate better the proteins dynamics. This investigation underscores a crucial insight: in modeling complex pathologies, the precision with which the mathematical framework is chosen is crucial, especially when validation against clinical data is considered decisive.
Alzheimers Disease AD is an acute neuro disease that degenerates the brain cells and thus leads to memory loss progressively. It is a fatal brain disease that mostly affects the elderly. It steers the decline of cognitive and biological functions of the brain and shrinks the brain successively, which in turn is known as Atrophy. For an accurate diagnosis of Alzheimers disease, cutting edge methods like machine learning are essential. Recently, machine learning has gained a lot of attention and popularity in the medical industry. As the illness progresses, those with Alzheimers have a far more difficult time doing even the most basic tasks, and in the worst case, their brain completely stops functioning. A persons likelihood of having early-stage Alzheimers disease may be determined using the ML method. In this analysis, papers on Alzheimers disease diagnosis based on deep learning techniques and reinforcement learning between 2008 and 2023 found in google scholar were studied. Sixty relevant papers obtained after the search was considered for this study. These papers were analysed based on the biomarkers of AD and the machine-learning techniques used. The analysis shows that deep l
Alzheimers Disease (AD) is a progressive neurodegenerative disorder that poses significant challenges in its early diagnosis, often leading to delayed treatment and poorer outcomes for patients. Traditional diagnostic methods, typically reliant on single data modalities, fall short of capturing the multifaceted nature of the disease. In this paper, we propose a novel multimodal framework for the early detection of AD that integrates data from three primary sources: MRI imaging, cognitive assessments, and biomarkers. This framework employs Convolutional Neural Networks (CNN) for analyzing MRI images and Long Short-Term Memory (LSTM) networks for processing cognitive and biomarker data. The system enhances diagnostic accuracy and reliability by aggregating results from these distinct modalities using advanced techniques like weighted averaging, even in incomplete data. The multimodal approach not only improves the robustness of the detection process but also enables the identification of AD at its earliest stages, offering a significant advantage over conventional methods. The integration of biomarkers and cognitive tests is particularly crucial, as these can detect Alzheimer's long
Alzheimer's disease (AD), a degenerative brain condition, can benefit from early prediction to slow its progression. As the disease progresses, patients typically undergo brain atrophy. Current prediction methods for Alzheimers disease largely involve analyzing morphological changes in brain images through manual feature extraction. This paper proposes a novel method, the Deformation-Aware Temporal Generative Network (DATGN), to automate the learning of morphological changes in brain images about disease progression for early prediction. Given the common occurrence of missing data in the temporal sequences of MRI images, DATGN initially interpolates incomplete sequences. Subsequently, a bidirectional temporal deformation-aware module guides the network in generating future MRI images that adhere to the disease's progression, facilitating early prediction of Alzheimer's disease. DATGN was tested for the generation of temporal sequences of future MRI images using the ADNI dataset, and the experimental results are competitive in terms of PSNR and MMSE image quality metrics. Furthermore, when DATGN-generated synthetic data was integrated into the SVM vs. CNN vs. 3DCNN-based classificat
Alzheimer's disease (AD) emerges from a complex interplay of molecular, cellular, and network-level disturbances that are not easily captured by traditional reductionist frameworks. Conventional analyses of gene expression often rely on thresholded correlation networks or clustering-based module detection, approaches that may obscure nonlinear structure and higher-order organization. Here, we introduce a comparative topological framework that makes use of topological data analysis (TDA) and the Mapper algorithm to detect discontinuities - localized disruptions in the topology of gene co-expression space between healthy and AD brain tissue. Using gene expression data from 3 brain regions, we mapped how AD reshapes the global topology of gene-gene relationships. Discontinuity hotspots were identified via variability-based node scoring and subjected to Gene Ontology Biological Process enrichment analysis. This work illustrates the potential of TDA to uncover disease-relevant structure in high-dimensional transcriptomic data and motivates broader application of shape-based comparative methods in neurodegeneration research and other areas that benefit from comparative analysis.
Understanding alterations in structural disorders in tissue or cells or building blocks, such as DNA or chromatin in the human brain, at the nano to submicron level provides us with efficient biomarkers for Alzheimers detection. Here, we report a dual photonics technique to detect nano- to submicron-scale alterations in brain tissues or cells and DNA or chromatin due to the early to late progression of Alzheimers disease in humans. Using a recently developed mesoscopic light transport technique, fine-focused nano-sensitive partial wave spectroscopy (PWS), we measure the degree of structural disorder in tissues. Furthermore, the chemical-specific inverse participation ratio technique (IPR) was used to measure the DNA or chromatin structural alterations. The results of the PWS and IPR experiments showed a significant increase in the degree of structural disorder at the nano to submicron scale at different stages of AD relative to their controls for both the tissue or cell and DNA cellular levels. The increase in the structural disorder in cells or tissues and DNA or chromatin in the nuclei can be attributed to higher mass density fluctuations in the tissue and DNA or chromatin damage
Early endolysosomal and autophagic defects are among the earliest cellular alterations observed in Alzheimers disease (AD), yet the molecular drivers linking amyloid precursor protein (APP) metabolism to vesicle trafficking dysfunction remain incompletely understood. The APP-derived fragment C99 has emerged as a potential upstream mediator of intracellular toxicity, but its impact on organelle homeostasis and its modulation by metabolic interventions remain unclear. Here, we show that neuronal expression of human C99 in Drosophila induces profound vesicular abnormalities, impaired autophagic turnover, and disrupted mitochondrial quality control. Ultrastructural analysis revealed extensive accumulation of enlarged vesicular compartments, accompanied by reduced mitochondrial turnover and accumulation of aged mitochondria. Treatment with the ketone body beta-hydroxybutyrate (BHB) restored autophagic cargo clearance, improved mitochondrial turnover, and normalized vesicular ultrastructure. These protective effects required neuronal ketone transport, indicating a neuron-intrinsic metabolic mechanism. Proteomic mapping of the C99-associated interactome revealed that ketone treatment remo
Alzheimers disease (AD) is a severe neurological brain disorder. It is not curable, but earlier detection can help improve symptoms in a great deal. The machine learning based approaches are popular and well motivated models for medical image processing tasks such as computer-aided diagnosis. These techniques can improve the process for accurate diagnosis of AD. In this paper, we investigate the performance of these techniques for AD detection and classification using brain MRI and PET images from the OASIS database. The proposed system takes advantage of the artificial neural network and support vector machines as classifiers, and principal component analysis as a feature extraction technique. The results indicate that the combined scheme achieves good accuracy and offers a significant advantage over the other approaches.
Previous works in the literature apply 3D spatial-only models on 4D functional MRI data leading to possible sub-par feature extraction to be used for downstream tasks like classification. In this work, we aim to develop a novel 4D convolution network to extract 4D joint temporal-spatial kernels that not only learn spatial information but in addition also capture temporal dynamics. Experimental results show promising performance in capturing spatial-temporal data in functional MRI compared to 3D models. The 4D CNN model improves Alzheimers disease diagnosis for rs-fMRI data, enabling earlier detection and better interventions. Future research could explore task-based fMRI applications and regression tasks, enhancing understanding of cognitive performance and disease progression.
The rise of Alzheimers Disease worldwide has prompted a search for efficient tools which can be used to predict deterioration in cognitive decline leading to dementia. In this paper, we explore the potential of survival machine learning as such a tool for building models capable of predicting not only deterioration but also the likely time to deterioration. We demonstrate good predictive ability (0.86 C-Index), lending support to its use in clinical investigation and prediction of Alzheimers Disease risk.
Existing research has shown the potential of classifying Alzheimers Disease (AD) from eye-tracking (ET) data with classifiers that rely on task-specific engineered features. In this paper, we investigate whether we can improve on existing results by using a Deep-Learning classifier trained end-to-end on raw ET data. This classifier (VTNet) uses a GRU and a CNN in parallel to leverage both visual (V) and temporal (T) representations of ET data and was previously used to detect user confusion while processing visual displays. A main challenge in applying VTNet to our target AD classification task is that the available ET data sequences are much longer than those used in the previous confusion detection task, pushing the limits of what is manageable by LSTM-based models. We discuss how we address this challenge and show that VTNet outperforms the state-of-the-art approaches in AD classification, providing encouraging evidence on the generality of this model to make predictions from ET data.
The most frequent kind of dementia of the nervous system, Alzheimer's disease, weakens several brain processes (such as memory) and eventually results in death. The clinical study uses magnetic resonance imaging to diagnose AD. Deep learning algorithms are capable of pattern recognition and feature extraction from the inputted raw data. As early diagnosis and stage detection are the most crucial elements in enhancing patient care and treatment outcomes, deep learning algorithms for MRI images have recently allowed for diagnosing a medical condition at the beginning stage and identifying particular symptoms of Alzheimer's disease. As a result, we aimed to analyze five specific studies focused on AD diagnosis using MRI-based deep learning algorithms between 2021 and 2023 in this study. To completely illustrate the differences between these techniques and comprehend how deep learning algorithms function, we attempted to explore selected approaches in depth.
Alzheimers disease is a deadly neurological condition, impairing important memory and brain functions. Alzheimers disease promotes brain shrinkage, ultimately leading to dementia. Dementia diagnosis typically takes 2.8 to 4.4 years after the first clinical indication. Advancements in computing and information technology have led to many techniques of studying Alzheimers disease. Early identification and therapy are crucial for preventing Alzheimers disease, as early-onset dementia hits people before the age of 65, while late-onset dementia occurs after this age. According to the 2015 World Alzheimers disease Report, there are 46.8 million individuals worldwide suffering from dementia, with an anticipated 74.7 million more by 2030 and 131.5 million by 2050. Deep Learning has outperformed conventional Machine Learning techniques by identifying intricate structures in high-dimensional data. Convolutional Neural Network (CNN) and Recurrent Neural Network (RNN), have achieved an accuracy of up to 96.0% for Alzheimers disease classification, and 84.2% for mild cognitive impairment (MCI) conversion prediction. There have been few literature surveys available on applying ML to predict deme
Accurate prediction of conversion from Mild Cognitive Impairment (MCI) to Alzheimers Diseases (AD) is essential for early intervention, however, developing reliable conversion predictive models is difficult to develop due to limited longitudinal data availability We evaluate TabPFN (Tabular Pre-Trained Foundation Network) against traditional machine learning methods for predicting 3 year MCI to AD conversion using the TADPOLE dataset derived from ADNI. Using multimodal biomarker features extracted from demographics, APOE4, MRI volumes, CSF markers, and PET imaging, we conducted an experimental comparison across varying training set sizes (N=50 to 1000) and models including XGBoost, Random Forest, LightGBM, and Logistic Regression. TabPFN achieved one the highest performance (AUC=0.892), outperforming LightGBM (AUC=0.860) and demonstrating advantages in low data settings. At N=50 training samples, TabPFN maintained strong AUC while the traditional machine learning models struggles at small training samples. These findings demonstrate that foundation models are promising for disease prediction in data limited scenarios, such as Alzheimers diseases.
Early and accurate classification of Alzheimers disease (AD) from brain MRI scans is essential for timely clinical intervention and improved patient outcomes. This study presents a comprehensive comparative analysis of five CNN architectures (EfficientNetB0, ResNet50, DenseNet201, MobileNetV3, VGG16), five Transformer-based models (ViT, ConvTransformer, PatchTransformer, MLP-Mixer, SimpleTransformer), and a proposed hybrid model named Evan_V2. All models were evaluated on a four-class AD classification task comprising Mild Dementia, Moderate Dementia, Non-Demented, and Very Mild Dementia categories. Experimental findings show that CNN architectures consistently achieved strong performance, with ResNet50 attaining 98.83% accuracy. Transformer models demonstrated competitive generalization capabilities, with ViT achieving the highest accuracy among them at 95.38%. However, individual Transformer variants exhibited greater class-specific instability. The proposed Evan_V2 hybrid model, which integrates outputs from ten CNN and Transformer architectures through feature-level fusion, achieved the best overall performance with 99.99% accuracy, 0.9989 F1-score, and 0.9968 ROC AUC. Confusio
Alzheimers disease (AD) is a brain disorder that develops slowly and mainly affects memory, thinking, language, and daily activities. It is one of the most common causes of dementia and creates many difficulties for patients as well as their families. In the early stage, the symptoms are often mild and may look like normal ageing. For this reason, many people are diagnosed late, when the disease has already progressed. At present, there is no complete cure for AD. Still, early detection can help doctors manage the condition better and take suitable steps at the right time. In this study, a machine learning model is proposed to detect the early stages of Alzheimers disease using clinical details, neuropsychological test scores, and neuroimaging-related measures. The data used in this work is collected from the Alzheimers Disease Neuroimaging Initiative (ADNI). As the dataset has missing values, iterative imputation is applied to fill them. The dataset also has class imbalance, which is handled using Borderline SVM-SMOTE. After that, feature selection is carried out using wrapper-based and embedded methods so that only important features are used for training. The selected features a
Early and reliable detection of Alzheimer's disease (AD) is crucial for timely clinical intervention and improved patient management. It also supports the evaluation of emerging therapeutic strategies. In this paper, we propose a Low-Rank Mixture of Experts (LoRA-MoE) deep learning framework for Alzheimer's disease diagnosis based on handwriting analysis. Handwriting signals provide a non-invasive and scalable digital biomarker that captures subtle cognitive-motor impairments associated with early AD progression. The proposed architecture allows multiple experts to specialize in different handwriting patterns while sharing a common base network. This design enables efficient learning of general representations while reducing interference between experts. Each expert is equipped with lightweight low-rank adapters. This mechanism significantly reduces the number of trainable parameters compared with standard Mixture of Experts (MoE) models and improves training stability. The proposed framework is evaluated on the Diagnosis AlzheimeR WIth haNdwriting (DARWIN) dataset. Extensive experiments are conducted, including ablation studies on key architectural parameters such as hidden dimens
Deep learning has been successful in predicting neurodegenerative disorders, such as Alzheimer's disease, from magnetic resonance imaging (MRI). Combining multiple imaging modalities, such as T1-weighted (T1) and diffusion-weighted imaging (DWI) scans, can increase diagnostic performance. However, complete multimodal datasets are not always available. We use a conditional denoising diffusion probabilistic model to impute missing DWI scans from T1 scans. We perform extensive experiments to evaluate whether such imputation improves the accuracy of uni-modal and bi-modal deep learning models for 3-way Alzheimer's disease classification-cognitively normal, mild cognitive impairment, and Alzheimer's disease. We observe improvements in several metrics, particularly those sensitive to minority classes, for several imputation configurations.